Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 2Admelog/Insulin Lispro
02 10Humalog
Main Therapeutic Indication : Diabetes
Currency : USD
2019 Revenue in Millions : 273
2018 Revenue in Millions : 101
Growth (%) : 169
Main Therapeutic Indication : Diabetes
Currency : USD
2018 Revenue in Millions : 105
2017 Revenue in Millions : 0
Growth (%) : NA
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 2,626
2019 Revenue in Millions : 2,821
Growth (%) : -7
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 2,453
2020 Revenue in Millions : 2,626
Growth (%) : -7
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 2,061
2021 Revenue in Millions : 2,453
Growth (%) : -16
Main Therapeutic Indication : Diabetes
Currency : USD
2023 Revenue in Millions : 1,663
2022 Revenue in Millions : 2,061
Growth (%) : -19
Main Therapeutic Indication : Diabetes
Currency : USD
2015 Revenue in Millions : 2,785
2014 Revenue in Millions : 2,842
Growth (%) : 2%
Main Therapeutic Indication : Diabetes
Currency : USD
2014 Revenue in Millions : 6.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Diabetes
Currency : USD
2016 Revenue in Millions : 2,769
2015 Revenue in Millions : 2,842
Growth (%) : -3
Main Therapeutic Indication : Diabetes
Currency : USD
2017 Revenue in Millions : 2,865
2016 Revenue in Millions : 2,769
Growth (%) : 3
LOOKING FOR A SUPPLIER?